APC and colonic neoplasm: MCI-030, a sulindac derivative recently reported as a novel PDE10A inhibitor with chemopreventive efficacy in the Apc+/min−FCCC mouse model of colon cancer [25], exhibited more potent anticancer activity, with IC50 values ranging from 0.53 μM to 0.56 μM in ovarian cancer cells (Fig. 3B right panel; Table S26).